Medicus Pharma Ltd. (MDCXW) stock
Close on Oct 30, 2026Market cap $118.78MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $118.78M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$56.66M
- EPS, diluted
- -$2.45
- Book value per share
- -$0.03
- Diluted shares
- 55M
Trading
- Previous close
- $0.21
- Open
- $0.21
- Day's range
- $0.21 – $0.21
- Volume
- 250
- Average volume (20 days)
- 1,235
- Beta (5 years)
- 1.38
- 52-week range
- $1.82 – $130.00
- RSI (14 days)
- 16.5
- Volatility (1 year)
- 135.3%
- Relative volume
- 1.04×
- WACC
- 11.9%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | MDCXW | S&P 500 | Difference | MDCXW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.0% | -0.9% | −29.1 pts | ||
| 3 months | -32.3% | +2.1% | −34.4 pts | ||
| Year to date | -73.8% | +11.7% | −85.4 pts | ||
| 1 year | -79.8% | +12.4% | −92.2 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Medicus Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- News
- News
- News
About Medicus Pharma
Pharmaceutical Preparations
Medicus Pharma Ltd. is a clinical-stage biotechnology company that identifies, acquires, and develops therapeutic assets through Phase 2 proof-of-concept. The company seeks to out-license these programs or establish strategic partnerships with pharmaceutical companies for late-stage development and commercialization. Its core development programs operate through subsidiaries SkinJect Inc. and Antev. SkinJect develops doxorubicin-containing dissolvable microneedle arrays as localized treatments for non-melanoma skin conditions, primarily basal cell carcinoma. Antev develops Teverelix, an injectable gonadotrophin-releasing hormone antagonist designed for individuals with advanced prostate cancer and high cardiovascular risk, as well as patients experiencing acute urinary retention episodes due to enlarged prostate.
Company profile, executives and historyMedicus Pharma stock: common questions
What is Medicus Pharma's stock price?
MDCXW closed at $0.21 on Oct 30, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $1.82 and $130.00.
What is Medicus Pharma's market cap?
Medicus Pharma was worth $118.78M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is MDCXW's P/E ratio?
Medicus Pharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$2.45), so it has no meaningful P/E ratio.
Does Medicus Pharma pay a dividend?
No. Medicus Pharma has not paid a cash dividend over the last twelve months.
How has MDCXW stock performed over the past year?
Including dividends, MDCXW returned -79.8% over the past year, against +12.4% for the S&P 500.
Who are Medicus Pharma's competitors?
Companies most similar to Medicus Pharma by business, industry and size include BDRX, KZIA, MREO, OCS, PTGX.